BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi TD, Zhang JM, Wang XF, Chen M, Sun H, Chen CB, Ren H. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med. 2012;12:105-113. [PMID: 21748522 DOI: 10.1007/s10238-011-0151-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng X, Luo YW, Yi XD. Relationship between antiviral therapy and PD-1/PD-L1 expression on immune cells in chronic hepatitis B patients. Shijie Huaren Xiaohua Zazhi 2015; 23(12): 1910-1916 [DOI: 10.11569/wcjd.v23.i12.1910] [Reference Citation Analysis]
2 Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. J Viral Hepat 2013;20:52-7. [DOI: 10.1111/jvh.12064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunol Lett 2017;190:206-12. [PMID: 28827021 DOI: 10.1016/j.imlet.2017.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Fu X, Lou H, Chen F, Gao X, Lin Z. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels. Clin Exp Med 2020;20:241-8. [PMID: 32052245 DOI: 10.1007/s10238-019-00603-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Meng N, Gao X, Yan W, Wang M, Liu P, Lu XD, Zhang SJ, Lu YQ, Tang WX. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci. 2015;35:230-234. [PMID: 25877357 DOI: 10.1007/s11596-015-1416-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Conroy MJ, Mac Nicholas R, Grealy R, Taylor M, Otegbayo JA, O’Dea S, Mulcahy F, Ryan T, Norris S, Doherty DG. Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon-γ or interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection. J Viral Hepat. 2015;22:335-345. [PMID: 25186004 DOI: 10.1111/jvh.12299] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
7 Yan Z, Qiao B, Zhang H, Wang Y, Gou W. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine (Baltimore) 2018;97:e11716. [PMID: 30075577 DOI: 10.1097/MD.0000000000011716] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat. 2013;20 Suppl 1:9-17. [PMID: 23458520 DOI: 10.1111/jvh.12059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
9 Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, Zhou J, Mao Q, Ni B. Effects of telbivudine treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm. 2012;2012:789859. [PMID: 22570512 DOI: 10.1155/2012/789859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
10 Zhang Y, Zhang WL, Pang XW, Wang LX, Wei X, Huang CX, Bai XF, Han S, Liu LN, Lian JQ. Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B. Virol J 2017;14:49. [PMID: 28274240 DOI: 10.1186/s12985-017-0712-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Lawrenczyk A, Kim S, Wen X, Xiong R, Yuan W. Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. Pathogens. 2014;3:563-576. [PMID: 25438012 DOI: 10.3390/pathogens3030563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Hao C, Wang J, Kang W, Xie Y, Zhou Y, Ma L, Peng M, Bai X, Lian J, Jia Z. Kinetics of Th17 Cytokines During Telbivudine Therapy in Patients With Chronic Hepatitis B. Viral Immunology 2013;26:336-42. [DOI: 10.1089/vim.2013.0032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore) 2017;96:e7021. [PMID: 28562554 DOI: 10.1097/MD.0000000000007021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
14 Bergantini L, Cameli P, d’Alessandro M, Vagaggini C, Refini R, Landi C, Pieroni M, Spalletti M, Sestini P, Bargagli E. NK and NKT-like cells in granulomatous and fibrotic lung diseases. Clin Exp Med 2019;19:487-94. [DOI: 10.1007/s10238-019-00578-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
15 Zhu H, Zhang Y, Liu H, Zhang Y, Kang Y, Mao R, Yang F, Zhou D, Zhang J. Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection. Medicine (Baltimore). 2015;94:e961. [PMID: 26091463 DOI: 10.1097/md.0000000000000961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
16 Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, Zhu R, Gao Z. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014;59:50-4. [DOI: 10.1016/j.jcv.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol 2014; 20(28): 9486-9496 [PMID: 25071343 DOI: 10.3748/wjg.v20.i28.9486] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]